# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY

I Background Information:

Gold Standard Diagnostics Borrelia burgdorferi IgM ELISA Test Kit

# D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>LSR</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 866.3830 -Treponema PallidumTreponemal Test Reagents</td><td rowspan=1 colspan=1>MI - Microbiology</td></tr></table>

# II Submission/Device Overview:

# A Purpose for Submission:

To obtain a substantial equivalence determination and FDA clearance for a new device and to obtain a substantial equivalence determination and FDA clearance for a modified intended use for a previously cleared medical device. This regulatory filing follows the FDA guidance document titled “Bundling Multiple Devices or Multiple Indications in a Single Submission”1. For these devices, bundling is appropriate since the device review presented scientific and regulatory issues that were most efficiently addressed during a single review. In determining whether a bundled submission was appropriate FDA considered that: (i) the supporting data are similar; (ii) primarily one review division/group will be involved; and (iii) the devices or indications for use are similar.

# B Measurand:

Anti-Borrelia burgdorferi antibodies

# C Type of Test:

Enzyme-linked immunosorbent assay (ELISA)

III Intended Use/Indications for Use:

A Intended Use(s): See Indications for Use below.

# B Indication(s) for Use:

Gold Standard Diagnostics Borrelia burgdorferi IgM ELISA Test Kit

The Gold Standard Diagnostics Borrelia burgdorferi IgM ELISA Test Kit is intended as a qualitative test for the detection of IgM antibodies to B. burgdorferi sensu stricto in human serum from symptomatic patients or people suspected of infection. When used as the first-tier screening test, positive and equivocal results must be supplemented through additional testing by one of the following methods:

a) Standard two-tier test methodology (STTT) using an IgM blot test following current interpretation guidelines, OR

b) Modified two-tier test methodology (MTTT) using the Gold Standard Diagnostics Borrelia burgdorferi VlsE-OspC IgG/IgM ELISA Test

The assay can also be used as a second-tier confirmation test using the MTTT methodology when used with when used with the Gold Standard Diagnostics Borrelia burgdorferi VlsE-OspC IgG/IgM ELISA Test as the first-tier screening test.

Positive test results by either the STTT or MTTT methodology are supportive evidence for the presence of antibodies and exposure to Borrelia burgdorferi, the cause of Lyme disease. A diagnosis of Lyme disease should be made based on the presence of Borrelia burgdorferi antibodies, history, symptoms, and other laboratory findings.

Gold Standard Diagnostics Borrelia burgdorferi VlsE-OspC IgG/IgM ELISA Test Kit

The Gold Standard Diagnostics Borrelia burgdorferi VlsE-OspC IgG/IgM ELISA Test Kit is intended as a qualitative test for the detection of IgG and IgM class antibodies to VlsE and OspC antigens from Borrelia burgdorferi sensu stricto in human serum from symptomatic patients or people suspected of having Lyme disease. When used as the first-tier screening test, positive and equivocal results must be confirmed through additional testing by one of the following methods:

a) Standard two-tier test methodology (STTT) using an IgG and/or IgM blot testing following current interpretation guidelines, OR

b) Modified two-tier test methodology (MTTT) using one or more of the following three ELISA based assays: Gold Standard Diagnostics Borrelia burgdorferi IgG/IgM ELISA Test, Gold Standard Diagnostics Borrelia burgdorferi IgG ELISA Test, Gold Standard Diagnostics Borrelia burgdorferi IgM ELISA Test.

The assay can also be used as a second-tier confirmation test using the MTTT methodology when used with one or more of the following three ELISA based assays: Gold Standard Diagnostics Borrelia burgdorferi $\mathrm { I g G / I g M }$ ELISA Test, Gold Standard Diagnostics Borrelia burgdorferi IgG ELISA Test, Gold Standard Diagnostics Borrelia burgdorferi IgM ELISA Test.

Positive test results by either the STTT or MTTT methodology are supportive evidence for the presence of antibodies and exposure to Borrelia burgdorferi, the cause of Lyme disease. A diagnosis of Lyme disease should be made based on the presence of Borrelia burgdorferi antibodies, history, symptoms, and other laboratory findings.

C Special Conditions for Use Statement(s): Rx - For Prescription Use Only

D Special Instrument Requirements: N/A

IV Device/System Characteristics:

# A Device Description:

The Gold Standard Diagnostics Borrelia burgdorferi IgM ELISA Test Kit is an Enzyme-linked immunosorbent assay (ELISA) for the qualitative detection of IgM antibodies to Borrelia burgdorferi in human serum.

During the test procedure, antibodies to B. burgdorferi (sensu stricto) if present in the human serum sample will bind to the antigens coated onto the wells forming antigen-antibody complexes. Excess antibodies are removed by washing. A conjugate of goat anti-human IgM antibodies conjugated with horseradish peroxidase is then added, which binds to the antigen-antibody complexes. Excess conjugate is removed by washing. This is followed by the addition of a chromogenic substrate, tetramethylbenzidine (TMB). If specific antibodies to the antigen are present in the patients’ serum, a blue color will develop. The enzymatic reaction is then stopped with a stopping solution causing the contents of the well to turn yellow. The wells are read photometrically with a microplate reader at $4 5 0 \mathrm { n m }$ .

The antigens used in the Gold Standard Diagnostics Borrelia burgdorferi IgM ELISA Test kit is a combination of B. burgdorferi sensu stricto strain B31 lysate, B. burgdorferi sensu stricto strain 2591 lysate, and a recombinant VlsE from B. burgdorferi sensu stricto strain B31. The lysates use spirochetes growing in BSK-H complete medium until mid-exponential phase. The recombinant VlsE protein is produced in E. coli SURE2 cells and purified by affinity chromatography. The purity of each antigen is assayed by SDS-PAGE followed by Coomassie staining and/or western blotting.

The kit includes $1 2 \times 8$ well Antigen Coated strips, Conjugate, Substrate, Stop Solution, Wash Buffer, Diluent, Negative Control, Positive Control, and a Cutoff Control. The controls are provided to determine if the assay is functioning properly and to determine the antibody level. The reagents are sufficient for 96 determinations.

# V Substantial Equivalence Information:

A Predicate Device Name(s): Gold Standard Diagnostics Borrelia burgdorferi IgM ELISA Test Kit, Borrelia burgdorferi Igm Blot Test   
B Predicate 510(k) Number(s): K200023

# C Comparison with Predicate(s):

<table><tr><td colspan="1" rowspan="1">Device &amp;PredicateDevice(s):</td><td colspan="1" rowspan="1">K203295</td><td colspan="1" rowspan="1">K200023</td><td colspan="1" rowspan="1">K113846</td></tr><tr><td colspan="1" rowspan="1">Device TradeName</td><td colspan="1" rowspan="1">Device 1: Gold StandardDiagnostics Borreliaburgdorferi IgM ELISATest KitDevice 2: Gold StandardDiagnostics Borreliaburgdorferi VlsE-OspCIgG/IgM ELISA Test Kit</td><td colspan="1" rowspan="1">Gold Standard DiagnosticsBorrelia burgdorferi IgMELISA Test Kit</td><td colspan="1" rowspan="1">Gold Standard DiagnosticsBorrelia burgdorferi IgMBlot Test Kit</td></tr><tr><td colspan="1" rowspan="1">GeneralDeviceCharacteristic Similarities</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">IntendedUse/Indications For Use</td><td colspan="1" rowspan="1">These are two ELISA assaysfor the qualitative detectionof B. burgdorferi antibodiesin human serum. For acomplete description of theIntended Use please seeItem III B. above</td><td colspan="1" rowspan="1">The Gold StandardDiagnostics Borreliaburgdorferi IgM ELISATest Kit is intended as aqualitative presumptive(first-step) test for thedetection of IgM antibodiesto B. burgdorferi sensustricto in human serum fromsymptomatic patients orpeople suspected ofinfection. Positive andequivocal results must besupplemented by testingwith a second-step Westernblot assay.</td><td colspan="1" rowspan="1">The Gold StandardDiagnostics Borreliaburgdorferi B31 IgM LineBlot Test Kit is intended forthe qualitative detection ofIgM antibodies to B.burgdorferi sensu stricto(B31) in human serum. Thistest is intended for use intesting human serumsamples which have beenfound positive or equivocalusing an ELISA or IFA testprocedure to providesupportive evidence ofinfection with B.burgdorferi.</td></tr><tr><td colspan="1" rowspan="1">SampleMatrix</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">SampleProcessing</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Dilute samples 1:100 inDiluent</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">ControlsProvided</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Positive, Cutoff, Negative</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Assay Type</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Qualitative</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">GeneralDeviceCharacteristic Differences</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Antigens</td><td colspan="1" rowspan="1">B. burgdorferi B31 strain,B. burgdorferi 2591 strain,B. burgdorferi recombinantVlsE protein from B31strainRecombinant VlsE andOspC from B. burgdorferistrain B31</td><td colspan="1" rowspan="1">B. burgdorferi B31 strain,B. burgdorferi 2591 strain,B. burgdorferi recombinantVlsE protein from B31strain</td><td colspan="1" rowspan="1">B. burgdorferi B31 strain</td></tr><tr><td colspan="1" rowspan="1">Assay Format</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Antigen coated microtiterplate - 96 wells</td><td colspan="1" rowspan="1">Nitrocellulose strips</td></tr><tr><td colspan="1" rowspan="1">Technology</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">ELISA</td><td colspan="1" rowspan="1">Immunoblot</td></tr><tr><td colspan="1" rowspan="1">ReagentsProvided</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Diluent, Wash, Conjugate,Substrate, Stop Solution</td><td colspan="1" rowspan="1">Diluent/Wash, Conjugate,Substrate</td></tr><tr><td colspan="1" rowspan="1">Volumes</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">100 μL sample, 50 µLsubstrate, 50 μL stopsolution</td><td colspan="1" rowspan="1">1500ul sample, 1500ulsubstrate</td></tr><tr><td colspan="1" rowspan="1">Incubation</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">15/15/15 minutes at roomtemperature</td><td colspan="1" rowspan="1">30/30/10-13 minutes atroom temperature</td></tr><tr><td colspan="1" rowspan="1">ReportedResults</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Positive, Equivocal,Negative</td><td colspan="1" rowspan="1">Positive, Negative</td></tr><tr><td colspan="1" rowspan="1">Interpretation</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Optical density readingsfrom Spectrophotometer</td><td colspan="1" rowspan="1">Visual</td></tr><tr><td colspan="1" rowspan="1">Resultsinterpretation</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Convert to units.Negative &lt;9Equivocal 9.0-11.0Positive &gt;11.0</td><td colspan="1" rowspan="1">Compare to cutoff band</td></tr></table>

# VI Standards/Guidance Documents Referenced:

None.

Note: This clearance is for a modified use for a previously cleared IVD, the Gold Standard Diagnostics Borrelia burgdorferi IgM ELISA Test Kit (K200023). Representative analytical study data are presented below.

# A Analytical Performance:

# 1. Precision/Reproducibility:

To determine the precision of the Gold Standard Diagnostics Borrelia burgdorferi IgM ELISA Test, a within-lab precision study was conducted. A precision panel consisting of a negative sample, a high negative sample, a low positive sample, and a moderate positive sample, along with the kit controls, was tested in-house. The sample panel was masked and randomized. Each of the panel members was tested in duplicate, twice per day, for 12 days. The results are summarized in the following table.

Table 1. Precision Study Results   

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>MeanUnits</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Between-Run</td><td rowspan=1 colspan=1>Between-Day</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=2 colspan=1>ModeratePositive</td><td rowspan=2 colspan=1>48</td><td rowspan=2 colspan=1>20.6</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>1.234</td><td rowspan=1 colspan=1>0.476</td><td rowspan=1 colspan=1>0.423</td><td rowspan=1 colspan=1>1.222</td></tr><tr><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>6.0%</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>5.9%</td></tr><tr><td rowspan=2 colspan=1>LowPositive</td><td rowspan=2 colspan=1>48</td><td rowspan=2 colspan=1>12.4</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.849</td><td rowspan=1 colspan=1>0.728</td><td rowspan=1 colspan=1>0.405</td><td rowspan=1 colspan=1>0.834</td></tr><tr><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>6.9%</td><td rowspan=1 colspan=1>5.9%</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>6.7%</td></tr><tr><td rowspan=2 colspan=1>HighNegative</td><td rowspan=2 colspan=1>48</td><td rowspan=2 colspan=1>5.7</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.740</td><td rowspan=1 colspan=1>0.495</td><td rowspan=1 colspan=1>0.349</td><td rowspan=1 colspan=1>0.727</td></tr><tr><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>13.1%</td><td rowspan=1 colspan=1>8.7%</td><td rowspan=1 colspan=1>6.2%</td><td rowspan=1 colspan=1>12.8%</td></tr><tr><td rowspan=2 colspan=1>Negative</td><td rowspan=2 colspan=1>48</td><td rowspan=2 colspan=1>2.5</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.328</td><td rowspan=1 colspan=1>0.103</td><td rowspan=1 colspan=1>0.061</td><td rowspan=1 colspan=1>0.324</td></tr><tr><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>13.3%</td><td rowspan=1 colspan=1>4.2%</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>13.1%</td></tr><tr><td rowspan=2 colspan=1>PositiveControl</td><td rowspan=2 colspan=1>48</td><td rowspan=2 colspan=1>25.2</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>1.197</td><td rowspan=1 colspan=1>0.337</td><td rowspan=1 colspan=1>0.492</td><td rowspan=1 colspan=1>1.183</td></tr><tr><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>4.7%</td></tr><tr><td rowspan=2 colspan=1>CutoffControl</td><td rowspan=2 colspan=1>48</td><td rowspan=2 colspan=1>9.9</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.317</td><td rowspan=1 colspan=1>0.238</td><td rowspan=1 colspan=1>0.305</td><td rowspan=1 colspan=1>0.287</td></tr><tr><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>3.2%</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>3.1%</td><td rowspan=1 colspan=1>2.9%</td></tr><tr><td rowspan=2 colspan=1>NegativeControl</td><td rowspan=2 colspan=1>48</td><td rowspan=2 colspan=1>0.7</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.124</td><td rowspan=1 colspan=1>0.052</td><td rowspan=1 colspan=1>0.017</td><td rowspan=1 colspan=1>0.123</td></tr><tr><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>18.1%</td><td rowspan=1 colspan=1>736%</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>17.9%</td></tr></table>

Reproducibility: A reproducibility panel consisting of a negative sample, a high negative sample, a low positive sample, and a moderate positive sample, along with the kit controls, was tested at three different sites. The sample panel was masked and randomized. Each of the panel members was tested in triplicate, twice per day, for five days. The Within-Run, Between-Run, Between-Days, and Between-Sites Standard Deviation and Coefficients of Variation (CV) were calculated. The results are summarized in the following table.

Table 2. Reproducibility Study Results

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>MeanUnits</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Within-Run</td><td rowspan=1 colspan=1>Between-Run</td><td rowspan=1 colspan=1>Between-Day</td><td rowspan=1 colspan=1>Between-Sites</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=2 colspan=1>ModeratePositive</td><td rowspan=2 colspan=1>90</td><td rowspan=2 colspan=1>54.4</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>3.26</td><td rowspan=1 colspan=1>1.37</td><td rowspan=1 colspan=1>2.49</td><td rowspan=1 colspan=1>1.38</td><td rowspan=1 colspan=1>3.73</td></tr><tr><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>6.0%</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>4.6%</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>6.9%</td></tr><tr><td rowspan=2 colspan=1>LowPositive</td><td rowspan=2 colspan=1>90</td><td rowspan=2 colspan=1>17.1</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>1.13</td><td rowspan=1 colspan=1>0.46</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>0.78</td><td rowspan=1 colspan=1>1.29</td></tr><tr><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>6.6%</td><td rowspan=1 colspan=1>2.8%</td><td rowspan=1 colspan=1>5.7%</td><td rowspan=1 colspan=1>4.6%</td><td rowspan=1 colspan=1>7.6%</td></tr><tr><td rowspan=2 colspan=1>HighNegative</td><td rowspan=2 colspan=1>90</td><td rowspan=2 colspan=1>6.5</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.60</td><td rowspan=1 colspan=1>0.34</td><td rowspan=1 colspan=1>0.48</td><td rowspan=1 colspan=1>0.56</td><td rowspan=1 colspan=1>0.75</td></tr><tr><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>9.2%</td><td rowspan=1 colspan=1>5.2%</td><td rowspan=1 colspan=1>7.4%</td><td rowspan=1 colspan=1>8.6%</td><td rowspan=1 colspan=1>11.4%</td></tr><tr><td rowspan=2 colspan=1>Negative</td><td rowspan=2 colspan=1>90</td><td rowspan=2 colspan=1>1.8</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.31</td><td rowspan=1 colspan=1>0.25</td><td rowspan=1 colspan=1>0.29</td><td rowspan=1 colspan=1>0.32</td><td rowspan=1 colspan=1>0.34</td></tr><tr><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>17.0%</td><td rowspan=1 colspan=1>14.3%</td><td rowspan=1 colspan=1>15.9%</td><td rowspan=1 colspan=1>17.5%</td><td rowspan=1 colspan=1>18.6%</td></tr><tr><td rowspan=2 colspan=1>PositiveControl</td><td rowspan=2 colspan=1>30</td><td rowspan=2 colspan=1>24.2</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>1.69</td><td rowspan=1 colspan=1>1.10</td><td rowspan=1 colspan=1>1.28</td><td rowspan=1 colspan=1>0.34</td><td rowspan=1 colspan=1>1.64</td></tr><tr><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>7.0%</td><td rowspan=1 colspan=1>7.0%</td><td rowspan=1 colspan=1>5.3%</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>6.8%</td></tr><tr><td rowspan=2 colspan=1>CutoffControl</td><td rowspan=2 colspan=1>60</td><td rowspan=2 colspan=1>9.9</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.36</td><td rowspan=1 colspan=1>0.17</td><td rowspan=1 colspan=1>0.22</td><td rowspan=1 colspan=1>1.33</td><td rowspan=1 colspan=1>0.34</td></tr><tr><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>3.6%</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>5.5%</td><td rowspan=1 colspan=1>3.4%</td></tr><tr><td rowspan=2 colspan=1>NegativeControl</td><td rowspan=2 colspan=1>30</td><td rowspan=2 colspan=1>0.7</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.72</td></tr><tr><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>13.3%</td><td rowspan=1 colspan=1>5.1%</td><td rowspan=1 colspan=1>5.1%</td><td rowspan=1 colspan=1>5.0%</td><td rowspan=1 colspan=1>13.1%</td></tr></table>

2. Linearity: Not Applicable.

3. Analytical Specificity/Interference:

Analytical Specificity: The analytical specificity was determined by testing 208 asymptomatic individuals’ samples from endemic and non-endemic regions. The Gold Standard Diagnostics Borrelia burgdorferi IgM ELISA Test results are summarized in the following table.

Table 3. Analytical Specificity Study   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Number of samples</td><td rowspan=1 colspan=1>NumberPositive/Equivocal</td><td rowspan=1 colspan=1>AnalyticalSpecificity</td></tr><tr><td rowspan=1 colspan=1>Endemic Region</td><td rowspan=1 colspan=1>103</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>96.1%</td></tr><tr><td rowspan=1 colspan=1>Non-endemic Region</td><td rowspan=1 colspan=1>105</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>90.5%</td></tr></table>

Cross-reactivity Study: A study using 277 samples was conducted to evaluate potential cross reactivity from different disease conditions. The samples were obtained from serum vendors who confirmed their positivity for each respective marker. The samples were tested on the Gold Standard Diagnostics Borrelia burgdorferi IgM ELISA Test. The results are summarized in the following table:

Table 4. Cross-reactivity Study Results   

<table><tr><td colspan="1" rowspan="1">Organism/Disease State</td><td colspan="1" rowspan="1">Samples Tested (N)</td><td colspan="1" rowspan="1"># Positive / (%)</td></tr><tr><td colspan="1" rowspan="1">Tick borne Relapsing FeverIgM</td><td colspan="1" rowspan="1">21</td><td colspan="1" rowspan="1">0 / 0%</td></tr><tr><td colspan="1" rowspan="1">Treponemal Infections</td><td colspan="1" rowspan="1">29</td><td colspan="1" rowspan="1">0/0%</td></tr><tr><td colspan="1" rowspan="1">Rickettsia IgM</td><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">0 /0%</td></tr><tr><td colspan="1" rowspan="1">Ehrlichiosis IgM</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">6 / 60%*</td></tr><tr><td colspan="1" rowspan="1">Babesiosis IgM</td><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">10 / 63%*</td></tr><tr><td colspan="1" rowspan="1">Leptospirosis IgM</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">8 / 80%*</td></tr><tr><td colspan="1" rowspan="1">Epstein-Barr Virus IgM</td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">0 /0%</td></tr><tr><td colspan="1" rowspan="1">H. pylori IgM</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">0 / 0%</td></tr><tr><td colspan="1" rowspan="1">Fibromyalgia</td><td colspan="1" rowspan="1">25</td><td colspan="1" rowspan="1">0 / 0%</td></tr><tr><td colspan="1" rowspan="1">Rheumatoid Arthritis</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">0 / 0%</td></tr><tr><td colspan="1" rowspan="1">Autoimmune Disease</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">0 / 0%</td></tr><tr><td colspan="1" rowspan="1">Multiple Sclerosis</td><td colspan="1" rowspan="1">22</td><td colspan="1" rowspan="1">0 / 0%</td></tr><tr><td colspan="1" rowspan="1">Severe Periodontitis</td><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">0 /0%</td></tr></table>

\* Samples were also positive by the predicate device

Interfering Substances Study: The effect of potential interfering substances on samples using the Gold Standard Diagnostics Borrelia burgdorferi $\mathrm { I g M }$ ELISA Test was evaluated Three samples, a negative, a low positive, and a moderate positive were spiked with high levels of interferants and were tested along with serum without spiked interferants. The recommended concentrations from the guideline “Interference Testing in Clinical Chemistry EP7-A2” from the Clinical and Laboratory Standards Institute were used. The tested substances did not affect the performance of the Gold Standard Diagnostics Borrelia burgdorferi $\mathrm { I g G / I g M }$ ELISA Test.

Table 5. Interference Testing Results   

<table><tr><td rowspan=1 colspan=1>Substance</td><td rowspan=1 colspan=1>Concentration</td><td rowspan=1 colspan=1>Interference</td></tr><tr><td rowspan=1 colspan=1>Albumin</td><td rowspan=1 colspan=1>60 mg/mL</td><td rowspan=1 colspan=1>None Detected</td></tr><tr><td rowspan=1 colspan=1>Bilirubin</td><td rowspan=1 colspan=1>0.4 mg/mL</td><td rowspan=1 colspan=1>None Detected</td></tr><tr><td rowspan=1 colspan=1>Cholesterol</td><td rowspan=1 colspan=1>4.0 mg/mL</td><td rowspan=1 colspan=1>None Detected</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>10 mg/mL</td><td rowspan=1 colspan=1>None Detected</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>15 mg/mL</td><td rowspan=1 colspan=1>None Detected</td></tr></table>

4. Assay Reportable Range: Not Applicable.

5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods): Not Applicable.

6. Detection Limit: Not Applicable.

7. Assay Cut-Off:

The cutoff was determined by testing a total of 208 normal sera which consisted of 103 sera from an endemic region of Lyme disease and 105 sera from a non-endemic region of Lyme disease. The mean plus two standard deviations was used to determine the assay cutoff. A known positive sample was then diluted to produce a ready to use cutoff control. An additional 194 samples consisting of 114 samples from different phases of Lyme disease, 8 negative healthy samples, 72 negative Lyme disease samples but do have other diseases that may cause serologic cross-reactivity, were tested. A receiver operating characteristics (ROC) analysis was performed to evaluate the performance of the assay and confirm that the chosen cutoff provided the best compromise between sensitivity and specificity.

# B Comparison Studies:

1. Method Comparison with Predicate Device:

Gold Standard Diagnostics MTTT-IgM ELISA Method Comparison: The Gold Standard Diagnostics Borrelia burgdorferi IgM ELISA Test was utilized in a MTTT (2-ELISA) protocol with the Gold Standard Diagnostics Borrelia burgdorferi VlsE-OspC IgG/IgM ELISA Test. The MTTT (2-ELISA) results were compared to the standard two-tier testing (STTT) using the Gold Standard Diagnostics Borrelia burgdorferi IgM ELISA followed by testing all positive and equivocal results on the predicate IgM blot test.

Comparison studies were conducted at three sites (one internal and two external reference laboratories) using prospective samples submitted for Lyme serology testing. Four hundred eighty-one (481) serum samples were tested on the Gold Standard Diagnostics Borrelia burgdorferi IgM ELISA Test. A total of 68 positive and equivocal samples were obtained.

In the STTT protocol the samples that were positive or equivocal $\scriptstyle ( \ n = 6 8 )$ ) were tested with the predicate B. burgdorferi IgM blot test. In the MTTT protocol the samples $\scriptstyle ( \mathrm { n = 6 8 } )$ ) were tested on a second ELISA, the Gold Standard Diagnostics Borrelia burgdorferi VlsE-OspC $\mathrm { I g G / I g M }$ ELISA Test. In the second-tier ELISA test, positive and equivocal results were considered positive. These testing strategies are summarized in the two figures below.

![](images/a59bb4894358beabe034c7d40aeaf05f82326bfda33effb816171665ade99a15.jpg)  
Figure 1. STTT-IgM Western Blot Algorithm (WB-STTT [IgM])

![](images/ed4d3c3d0a216cb72a1ac233100e3d862873bf0d579d3866b370851140c6dc71.jpg)

Performance of the secont-tier Gold Standard Diagnostics VlsE-OspC ELISA was assessed by comparing results to second-tier western blot testing on only those samples positive by the first-tier Gold Standard Diagnostics Borrelia burgdorferi IgM ELISA.

Table 6. Second-tier Performance Summary First-tier Positives Only   

<table><tr><td rowspan=1 colspan=3>Predicate Western Blot [IgM]</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=2 colspan=1>Gold StandardDiagnosticsVlsE-OspCELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>40</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>28</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>68</td></tr></table>

PPA: $100 \%$ (20/20) $9 5 \%$ CI: $8 3 . 2 \mathrm { - } 1 0 0 . 0 \%$ NPA: $5 8 . 3 \%$ (28/48) $9 5 \%$ CI: $4 3 . 2 \substack { - 7 2 . 4 \% }$

The results of the MTTT when compared to the STTT, including all samples that were part of the prospective study $\scriptstyle ( \mathrm { n = 4 8 1 } )$ ), are summarized in the following table:

Table 7. Performance Summary - ELISA-MTTT [IgM] compared to WB-STTT [IgM]   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2>WB-STTT [IgM]</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=2 colspan=1>Gold StandardDiagnosticsELISA-MTTT[IgM]</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>40</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>441</td><td rowspan=1 colspan=1>441</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>461</td><td rowspan=1 colspan=1>481</td></tr></table>

PPA: $100 \%$ (20/20) $9 5 \%$ CI: $8 3 . 2 \substack { - 1 0 0 \% }$ NPA: $9 5 . 7 \%$ (441/461) $9 5 \%$ CI: $9 3 . 4 \substack { - 9 7 . 3 \% }$

The above performance table artificially inflates the negative percent agreement of the second-tier test since a large number of negatives are negative by the first tier test.

2. Matrix Comparison: Not Applicable.

# C Clinical Studies:

1. Clinical Sensitivity:

Sensitivity Study: A sensitivity study was performed on 125 clinically characterized samples. The samples encompass early, disseminated, and late stages of Lyme disease. The samples were tested on both the Gold Standard Diagnostics ELISA-MTTT [IgM] algorithm and the predicate WB-STTT [IgM] algorithm. The results are summarized in the following table:

Table 8. Sensitivity Study Results - Comparison of ELISA-MTTT [IgM] and WB-STTT $[ \mathrm { I g } \mathrm { M } ]$ algorithms   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=2 colspan=1>N</td><td rowspan=1 colspan=2>Gold StandardDiagnostics ELISA-MTTT[IgM]</td><td rowspan=1 colspan=2>Predicate WB-STTT[IgM]</td></tr><tr><td rowspan=1 colspan=1>Disease Stage</td><td rowspan=1 colspan=1>Positive/Eqv.</td><td rowspan=1 colspan=1>%Agreementwith ClinicalDiagnosis</td><td rowspan=1 colspan=1>Positive/Eqv.</td><td rowspan=1 colspan=1>%AgreementwithClinicalDiagnosis</td></tr><tr><td rowspan=1 colspan=1>Early</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>39</td><td rowspan=1 colspan=1>62.9%</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>64.5%</td></tr><tr><td rowspan=1 colspan=1>Disseminated</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Late</td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>82.9%</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>22.0%</td></tr></table>

CDC Reference Panel: A panel of 280 positive and negative specimens from the Centers of Disease Control (CDC) for Lyme disease detection was tested on both the Gold Standard Diagnostics MTTT-IgM and on the predicate STTT- $\mathrm { \cdot } \mathrm { I g M }$ . The results are summarized in the following table:

Table 9. CDC Reference Panel Results - Comparison of ELISA-MTTT [IgM] and WB-STTT [IgM] algorithms   

<table><tr><td colspan="1" rowspan="2">SampleCategory</td><td colspan="2" rowspan="1">Gold Standard Diagnostics ELISA-MTTT [IgM]</td><td colspan="2" rowspan="1">Predicate WB-STTT [IgM]</td></tr><tr><td colspan="1" rowspan="1">Pos.</td><td colspan="1" rowspan="1">% Agreement withClinical Diagnosis</td><td colspan="1" rowspan="1">Pos.</td><td colspan="1" rowspan="1">% Agreement withClinical Diagnosis</td></tr><tr><td colspan="1" rowspan="1">Early Lyme(N = 60)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">76.7%</td><td colspan="1" rowspan="1">30</td><td colspan="1" rowspan="1">50.0%</td></tr><tr><td colspan="1" rowspan="1">CardiacLyme(N = 3)</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">66.7%</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">66.7%</td></tr><tr><td colspan="1" rowspan="1">NeurologicalLyme(N = 7)</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">100%</td></tr><tr><td colspan="1" rowspan="1">Late Lyme(N = 20)</td><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">80%</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">35%</td></tr><tr><td colspan="1" rowspan="1">HealthyControls(N = 100)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">99%</td></tr><tr><td colspan="1" rowspan="1">DiseaseControls(N -90)</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">96.7%</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">97.8%</td></tr></table>

2. Clinical Specificity: Not Applicable.

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable): Not Applicable.

# D Clinical Cut-Off:

Not Applicable.

# E Expected Values/Reference Range:

The range of values and positivity rate among different studies and population for the Gold Standard Diagnostics Borrelia burgdorferi IgM ELISA Test are as follows:

Table 10. Expected values of the Gold Standard Diagnostics Borrelia burgdorferi IgM ELISA Test   

<table><tr><td rowspan=2 colspan=1>Population</td><td rowspan=2 colspan=1># Samples</td><td rowspan=1 colspan=3>Unit Results</td><td rowspan=1 colspan=2>Qualitative Results</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>Std. Dev.</td><td rowspan=1 colspan=1># Positive/Equivocal</td><td rowspan=1 colspan=1>% Positive/Equivocal</td></tr><tr><td rowspan=1 colspan=1>NormalEndemic</td><td rowspan=1 colspan=1>103</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>0.4 - 10.7</td><td rowspan=1 colspan=1>2.341</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>3.9%</td></tr><tr><td rowspan=1 colspan=1>NormalNon-Endemic</td><td rowspan=1 colspan=1>105</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>0.0 - 15.5</td><td rowspan=1 colspan=1>3.136</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>9.5%</td></tr><tr><td rowspan=1 colspan=1>ProspectiveStudy</td><td rowspan=1 colspan=1>531</td><td rowspan=1 colspan=1>7.7</td><td rowspan=1 colspan=1>0.0 - 76.6</td><td rowspan=1 colspan=1>11.742</td><td rowspan=1 colspan=1>103</td><td rowspan=1 colspan=1>19.4%</td></tr><tr><td rowspan=1 colspan=1>SensitivityStudy</td><td rowspan=1 colspan=1>114</td><td rowspan=1 colspan=1>32.6</td><td rowspan=1 colspan=1>0.0 - 81.0</td><td rowspan=1 colspan=1>21.138</td><td rowspan=1 colspan=1>96</td><td rowspan=1 colspan=1>84.2%</td></tr></table>

# VIII Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.